Targeting TAO kinases using a new inhibitor compound delays mitosis and induces mitotic cell death in centrosome amplified breast cancer cells by Koo, Chuay Yeng et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1158/1535-7163.MCT-17-0077
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Koo, C. Y., Giacomini, C., Reyes-Corral, M., Olmos, Y., Tavares, I. A., Marson, C. M., ... Morris, J. D. H. (2017).
Targeting TAO kinases using a new inhibitor compound delays mitosis and induces mitotic cell death in
centrosome amplified breast cancer cells. MOLECULAR CANCER THERAPEUTICS, 16(11), 2410-2421.
https://doi.org/10.1158/1535-7163.MCT-17-0077
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019






1 
 
Targeting TAO kinases using a new inhibitor compound delays mitosis and induces mitotic cell 
death in centrosome amplified breast cancer cells. 
Chuay-Yeng Koo
1
, Caterina Giacomini
1
, Marta Reyes-Corral
1
, Yolanda Olmos
1
, Ignatius A. 
Tavares
1
, Charles M. Marson
2
, Spiros Linardopoulos
3
, Andrew N. Tutt
3, 4
 and Jonathan D.H. 
Morris
1
. 
1King’s College London, School of Cancer Sciences, New Hunt’s House, Guy’s Campus, Great 
Maze Pond, London SE11UL, UK 
2
University College London, Department of Chemistry, Christopher Ingold Laboratories, 20 
Gordon Street, London WC1H0AJ, UK 
3
The Institute of Cancer Research & Breast Cancer Now Toby Robins Research Centre, 237 
Fulham Road, London SW36JB, UK 
4King’s College London, School of Cancer Sciences, Breast Cancer Now Research Unit, Guy’s 
Cancer Centre, Guy’s Hospital, London SE19RT, UK 
 
Running title: TAOK inhibitor compound targets mitotic breast cancer cells 
Keywords: TAOK, breast, cancer, kinase and mitosis 
Financial support: Breast Cancer Now Project Grant (2012NovPR027) awarded to J.D.H. Morris 
and A.N. Tutt. Alzheimer’s Research UK Project Grant (IRG2014-6) awarded to J.D.H. Morris 
and D.H. Hanger.  
* Corresponding author: Jonathan D.H. Morris, King’s College London, School of Cancer 
Sciences, New Hunt’s House, Guy’s Campus, Great Maze Pond, London SE11UL; Phone (44)-
20-78488302; FAX (44)-20-78486220; E-mail: jonathan.morris@kcl.ac.uk 
 
 
 
2 
 
Abstract  
Thousand-and-one amino acid kinases (TAOKs) 1 and 2 are activated catalytically during 
mitosis and can contribute to mitotic cell rounding and spindle positioning. Here, we characterize 
a compound that inhibits TAOK1 and TAOK2 activity with IC50 values of 11-15 nM, is ATP-
competitive and targets these kinases selectively. TAOK inhibition or depletion in centrosome 
amplified SKBR3 or BT549 breast cancer cell models increases the mitotic population, the 
percentages of mitotic cells displaying amplified centrosomes and multipolar spindles, induces 
cell death and inhibits cell growth. In contrast, non-tumorigenic and dividing bipolar MCF-10A 
breast cells appear less dependent on TAOK activity and can complete mitosis and proliferate in 
the presence of the TAOK inhibitor. We demonstrate that TAOK1 and TAOK2 localize to the 
cytoplasm and centrosomes respectively during mitosis. Live cell imaging shows that the TAOK 
inhibitor prolongs the duration of mitosis in SKBR3 cells, increases mitotic cell death and 
reduces the percentages of cells exiting mitosis, whereas MCF-10A cells continue to divide and 
proliferate. Over 80% of breast cancer tissues display supernumerary centrosomes and tumor 
cells frequently cluster extra centrosomes to avoid multipolar mitoses and associated cell death. 
Consequently, drugs that stimulate centrosome declustering and induce multipolarity are likely to 
target dividing centrosome amplified cancer cells preferentially, whilst sparing normal bipolar 
cells. Our results demonstrate that TAOK inhibition can enhance centrosome declustering and 
mitotic catastrophe in cancer cells and these proteins may therefore offer novel therapeutic 
targets suitable for drug inhibition and the potential treatment of breast cancers, where 
supernumerary centrosomes occur.  
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Introduction 
Thousand-and-one amino acid kinases (TAOKs, also referred to as PSKs) belong to the sterile 20 
(STE20) group of kinases and subfamily members include TAOK1, TAOK2 and TAOK3 (1-6). 
TAOKs can regulate mitogen-activated protein kinase (MAPK) signaling pathways and TAOK1 
or TAOK2, but not TAOK3, stimulate c-Jun N-terminal kinase (JNK) and p38 MAPKs (1-5). 
TAOK1 and TAOK2 also induce apoptotic morphological changes via their activation of JNK 
MAPK and caspases (4, 5). Additional studies have shown that TAOKs can regulate microtubule 
(MT) dynamics and organization (7-9). TAOK1 induces MT instability via activation of MT-
affinity-regulating kinase (MARK/PAR-1) and phosphorylation of the MT-associated protein 
tau, which dissociates from MTs, resulting in their disassembly (8-11). TAOK2 can bind to MTs 
via its C terminus (amino acids 745-1235) and produces stabilized perinuclear MT cables that are 
nocodazole-resistant (7). TAOKs appear to be activated during MT-dependent processes when 
increases in MT dynamics occur, and these events include mitosis and neuritogenesis (12, 13). 
Our recent work using small interfering RNA (siRNA) to deplete TAOK1 or TAOK2 has shown 
that these proteins are required for mitotic cell rounding and spindle positioning, consistent with 
functional roles for these proteins in regulating MTs and mitosis (12).  
Many cancer drugs are anti-proliferative and disrupt MTs during cell division and include the 
original anti-mitotic drugs such as taxanes and vinca alkaloids (14, 15). Perturbation of the 
mitotic spindle results in erroneous chromosome alignment and activation of the spindle-
assembly checkpoint, which prevents mitotic progression and results in cell death (16, 17). 
Mitotic catastrophe provides an onco-suppressive mechanism that is activated during or after 
defective mitosis and results in cell death or senescence that is distinct from apoptosis (18, 19). 
Cell death may occur during mitosis or after premature slippage out of mitosis or alternatively, 
cells may become senescent in the subsequent G1 phase of the cell cycle following mitotic 
slippage (18, 19). Mitotic catastrophe therefore provides a mechanism for avoiding genomic 
instability, however, its induction may also provide a therapeutic opportunity whereby drugs and 
microtubule poisons disrupt the mitotic machinery and induce cancer cell death. Conventional 
MT-targeting drugs such as docetaxel, paclitaxel and epothilones, have proven to be clinically 
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effective and are relatively cancer specific but these compounds are also prone to debilitating 
side effects and patient relapse commonly occurs due to drug resistance (14, 20, 21). 
Consequently, current efforts are underway to develop a new generation of mitosis-selective 
drugs that are designed to inhibit proteins with essential roles in mitosis. Classic mitotic kinases 
such as the cyclin-dependent kinases, Polo-like kinases and Aurora kinases have been targeted 
already and showed efficacy in recent clinical trials, however, these drugs also appear to have 
limited efficacy in solid tumors and can cause severe side effects (22-25).  
Additional strategies are now required to target cancer specific events that are essential for tumor 
cell survival. Many solid and hematological cancers exhibit supernumerary centrosomes and 
tumor cells often cluster extra centrosomes to produce a functional bipolar-like spindle. Drugs 
that induce declustering of centrosomes and stimulate multipolar mitosis and cell death could 
therefore target and kill cancer cells selectively. Here we have characterized a small molecule 
inhibitor of the TAOK family of protein kinases and shown that TAOK inhibition can increase 
centrosome declustering, delay mitotic progression and induce mitotic catastrophe in centrosome 
amplified SKBR3 breast cancer cells. In contrast, non-tumorigenic and bipolar MCF-10A breast 
cells appear more resistant to the TAOK inhibitor and continue to divide in its presence. 
Materials and Methods 
Reagents and antibodies  
PRK5-MYC vector, pRK5-MYC-TAOK1, pRK5-MYC-TAOK1 (K57A), pRK5-MYC-TAOK2 
and pRK5-MYC-TAOK2 (K57A) were made as described previously (1, 5). PCMV-FLAG-
JNK1 was a gift from Dr M. Karin (University of California, USA). Small interfering RNA 
(siRNA) oligonucleotide sequences targeting TAOK1 (#1 and #4) or TAOK2 (#1 and #4) were 
described previously (12). Recombinant TAOK1 (1-319) and TAOK2 (1-319) were purchased 
from SignalChem (#T24-11G, #T25-11G). Rabbit TAOK1 or TAOK2 antibodies were obtained 
from Proteintech (#26250, #21188) and TAOK-pS181 antibody was produced by Eurogentec 
(4). Rabbit anti-FLAG and mouse anti-α-tubulin (DM1A) or anti-MYC antibodies and DAPI 
were obtained from Sigma-Aldrich (#F7425, #T9026, #M5546), and rabbit anti-JNK-
pT183/Y185 antibody was purchased from Cell Signaling Technology (#9251). Mouse anti-GFP 
antibodies were obtained from Millipore (#MAB3850). Rabbit anti-pericentrin and anti-α-tubulin 
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antibodies were purchased from AbCam (#ab44481, #ab18251). Goat anti-rabbit Alexa-Fluor568 
and Goat anti-mouse Alexa-Fluor488 antibodies were obtained from ThermoFisher Scientific 
(#A11036, #A11029).  
Cell culture and overexpression or knockdown of TAOKs 
Cell lines were obtained from ATCC (2008) and authenticated with karyotyping and short 
tandem repeat DNA profiling (2014). Cells were frozen within 4 weeks of purchase and used 
within 10 weeks after resuscitation and media checked routinely for mycoplasma using DAPI 
staining. MCF10-A cells were grown in DMEM/F12 Ham medium containing 5% horse serum 
(Sigma-Aldrich, #H1138), 20 ng/ml EGF (Sigma-Aldrich, #E4127), 100 ng/ml cholera toxin 
(Sigma-Aldrich, #C8052), 500 ng/ml hydrocortisone (Sigma-Aldrich, #H4001) and 10 µg/ml 
insulin (Sigma-Aldrich, #I9278). SKBR3 cells were maintained in McCoy’s/5A medium 
supplemented with 10% FCS. COS1 cells were grown in DMEM supplemented with 10% FCS. 
BT549 cells were grown in RPMI containing 10 µg/ml insulin and 10% FCS (ThermoFisher 
#10270). All media contained antibiotics and cultures grown in a humidified atmosphere (10% 
CO2, 37
o
C). For soft agar growth and colony formation assays, cells were plated in growth 
medium and 0.3% SeaPlaque low-melting agarose (Lonza, #50101). The bottom layer was made 
up of growth medium and 0.6% agarose. Colonies were stained with 0.005% crystal violet. For 
transfection, cells were treated with the indicated plasmids and Lipofectamine 2000 according to 
the manufacturer’s instructions (ThermoFisher Scientific, #1166027). For TAOK depletion 
experiments, growing cells were treated with the indicated siRNA (50 nM) oligonucleotides 
targeting TAOKs and HiPerFect (Qiagen, #301705) as described previously and cells on the 
culture plate and in the media pooled to determine cell numbers (12).    
Immunoprecipitation and Western blot analysis 
Transfected COS1 cells were incubated for 22 hours and then extracted in lysis buffer (500 µl) 
(12). For immunoprecipitation, samples were mixed with 15 µl of mouse anti-FLAG-agarose 
beads (Sigma-Aldrich, #A2220) for 2 hours/4
o
C and then washed in lysis buffer (x4) and bead 
pellets extracted in gel sample buffer. Protein extracts were resolved by SDS-PAGE (10%) 
followed by immunoblotting with the indicated antibodies and blot patterns analyzed using ECL 
and densitometry (1).  
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Flow cytometry 
Cells were treated with compound 43 (10 µM or equivalent DMSO) for 24-72 hours. To 
determine the mitotic fraction, cells were fixed with 2% PFA/PBS for 10 minutes, permeabilized 
with 90% methanol and blocked in 0.5% BSA/PBS before staining with Alexa-Fuor488-
histoneH3-pS10 antibody (Cell Signaling Technology #3465, 1 hour). Cells were then washed 
twice and stained with Propidium Iodide (PI). To assess apoptosis, FITC-Annexin V antibody 
(ThermoFisher Scientific #A13201) was used. Cells were resuspended in Annexin-binding 
buffer and stained with 5 µl of FITC-Annexin V antibody and PI for 30 minutes. Fluorescence 
from both assays was measured using a FACS Canto II flow cytometer (BD Technologies). 
Immunostaining, confocal and time-lapse video microscopy 
Growing cells on coverslips were fixed with ice-cold methanol (5 minutes/4 
o
C) or 4% 
paraformaldehyde/PBS (15 minutes/RT). Alternatively, SKBR3 cells containing doxycycline-
inducible pRetroX-TRE3G-GFP-TAOK plasmids were seeded on poly-L-lysine coated 
coverslips and incubated with 10 ng/µl doxycycline (Sigma-Aldrich, #D9891) for 24 hours 
before fixation. Samples were costained with the indicated antibodies and DAPI (3 µM) and 
processed as described previously (12), and cells imaged using a CSU-X1 inverted spinning-disk 
confocal microscope (Nikon) equipped with a EM-CCD camera (Andor iXon3) and a 100x/1.40 
NA oil objective (Nikon). Z-stacks were taken using a 0.3 μm step size. For time-lapse video 
imaging and mitotic cell analysis, MCF-10A or SKBR3 cells expressing GFP-α-tubulin 
constitutively were seeded onto a 24-well plate (Ibidi) and incubated overnight. Cultures were 
treated with compound 43 or DMSO as indicated and imaged at 15 minute intervals over a 48 
hour period. Time-lapse imaging was carried out using an Eclipse Ti-E Inverted microscope 
(Nikon), equipped with a 20x air objective (Nikon), a cooled CCD camera (CoolSNAP HQ2, 
Photometrics) and a climate-controlled chamber (37°C/5% CO2). The time of mitotic duration 
(nuclear envelope breakdown to cytokinesis) and mitotic catastrophe or exit from mitosis was 
determined by visual inspection and scoring of >120 individual cells per condition and for each 
experiment (n = 3).  
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TAOK inhibitor compounds  
Compounds 43 and 63 were synthesized by Evotec Limited (UK) and characterized using 
KinaseProfiler
TM
 services provided by Eurofins (UK) (Supplementary Methods).  
Statistical analysis 
Graphs and statistical analysis one-way or two-way ANOVA followed by a Bonferroni 
correction were performed using GraphPad and results are presented as mean ± SD. 
 
Results 
Identification and synthesis of small molecule inhibitors for TAO kinases 
Our previous studies have used siRNA to demonstrate that TAOK1 and TAOK2 expression in 
HeLa cells is required for mitotic cell rounding and spindle positioning, and these results suggest 
that small molecule TAOK inhibitors are likely to perturb malignant cell division (12). 
Currently, no effective TAOK inhibitors have been reported in the literature however, Exelixis 
Inc. (USA) have patented several compounds that may inhibit TAOKs with IC50 values ≤ 50nM 
(WO2005/040355A2) (26). Two of these compounds were synthesized for this study by Evotec 
(UK) and include N-[2-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]biphenyl-4-
carboxamide (referred to hereafter as compound 43 using Exelixis Inc. nomenclature) and N-{3-
[(2-{[6-methoxy-1,3-benzothiazol-2-yl]amino}-2-oxoethyl)amino]-3-oxo-1-
phenylpropyl}benzamide (referred to hereafter as compound 63) (Fig. 1A). 
Compounds 43 and 63 inhibit TAOK activity in vitro 
Initial experiments set out to confirm that both compounds could inhibit TAOK catalytic activity 
in in vitro kinase assays. Purified TAOKs were incubated with concentrations of compound 43 
or 63 between 0 and 30 µM; both compounds inhibit MBP phosphorylation by TAOK1 or 
TAOK2 potently (Fig. 1B). Calculated IC50 values for TAOK inhibition by compound 43 were 
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11 nM for TAOK1 and 15 nM for TAOK2 (Fig. 1B). Compound 63 also inhibited TAOK 
activity with IC50 values of 19 nM for TAOK1 and 39 nM for TAOK2 (Fig. 1B).  
 
Compounds 43 and 63 inhibit TAOK activity selectively 
The specificity of compound inhibition for TAOKs was examined by repeating in vitro kinase 
assays using 70 different kinases. TAOK1 or TAOK2 retained 8% and 11% of their activity 
respectively; when incubated in the presence of compound 43 (0.3 µM) and compared to control 
samples (Fig. 1C). Of the other kinases examined here, TAOK3 was inhibited and retained 13% 
activity. Three structurally related STE20 family members, LOK (48% activity retained), TAK1 
(53% activity retained) and PAK2 (79% activity retained) were also inhibited by compound 43, 
albeit to a lesser extent than the TAOKs. In addition, EphB4 (61% activity retained) and Aurora-
B (82% activity retained) are inhibited partially by this small molecule, however, the remaining 
62 kinases tested here retained ≥ 80% of their activity in the presence of compound 43 (Fig. 1C 
and Supplementary Table S1). TAOK1 or TAOK2 also retained 11% of their activity, when 
incubated with compound 63 (0.3 µM) and compared to control samples (Fig. 1C). Of the other 
kinases analyzed, TAOK3 was inhibited and retained 13% of activity whereas ALK retained 
64% activity, CDK9 retained 67% activity, SAPK2a and RSK1 retained 77% activity and 
DRAK1 retained 70% activity, in the presence of compound 63 (Fig. 1C). Sixty two other 
kinases retained ≥ 80% of their activity when incubated with compound 63 (Fig. 1C and 
Supplementary Table S1). Notably, the mitotic kinases Aurora A and B, Plk1 and 3, as well as 
CDK1 and 2 retain ≥ 80% of their catalytic activity with either compound (Fig. 1C). These 
results demonstrate that compounds 43 and 63 inhibit the catalytic activity of TAOKs 
selectively, when compared to their effects on alternative kinases.  
Compounds 43 and 63 are ATP-competitive inhibitors of TAOK activity 
ATP-competitive binding assays were carried out to investigate the mechanism of action for both 
TAOK inhibitors. In vitro kinase assays were repeated using nine concentrations of either 
compound 43 or 63 (between 0 and 1 µM), ATP (1, 10 or 155 µM) and purified TAOK1 or 
TAOK2. For compound 43, increasing [ATP] from 10 to 155 µM raised the calculated IC50 
values from 5 to 139 nM for TAOK1, and from 7 to 137 nM for TAOK2 (Supplementary Fig. 
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S1A). For compound 63, increasing [ATP] from 10 to 155 µM raised the calculated IC50 values 
from 20 to 170 nM for TAOK1, and from 28 to 221 nM for TAOK2 (Supplementary Fig. S1B). 
Both compounds are therefore ATP-competitive inhibitors of TAOK1 or TAOK2 activity.  
Compound 43 inhibits TAOK stimulation of JNK in cells 
Exogenous TAOK1 or TAOK2 can stimulate the phosphorylation and activation of JNK MAPK 
in cells, and this downstream response to these kinases was used here to test whether the 
compounds could inhibit TAOK activity in cells (1, 5). COS1 cells were cotransfected with 
FLAG-tagged JNK and MYC-tagged TAOK1 or TAOK2 and cultures incubated with 
compound. FLAG-tagged JNK was immunoprecipitated from cell lysates and changes in the 
phosphorylation and activation of FLAG-JNK determined by immunoblotting samples with the 
anti-active phospho-JNK-pT183/Y185 antibody. Exogenous TAOK1 or TAOK2 stimulation of 
JNK phosphorylation was inhibited by compound 43 at ≥ 10 µM and the levels of JNK-
pT183/Y185 reduced to those present in control cells transfected with empty vector or kinase-
defective TAOK1 (K57A) or TAOK2 (K57A) (Fig. 2A-B). These results demonstrate that 
compound 43 can inhibit TAOK stimulation of JNK phosphorylation in cells. In contrast, 
compound 63 was unable to prevent the stimulation of JNK phosphorylation by exogenous 
TAOK1 or TAOK2 in transfected cells indicating that this small molecule may not be suitable 
for targeting and inhibiting TAOK activity in cells (Supplementary Fig. S1C). Consequently, all 
further experiments were carried out using compound 43. 
TAOKs localize to the cytoplasm and centrosomes during mitosis 
Supernumerary centrosomes are a common feature of high grade and invasive cancers and a 
number of breast cancer cell lines were screened to identify appropriate models to represent this 
aberrant phenotype (27, 28). Cultures were fixed and costained with antibodies to detect 
pericentrin (centrosomes) and α-tubulin (MTs) plus  DAPI (DNA), and significant centrosome 
amplification (CA, > 2) was observed in dividing SKBR3 (38 ± 2% of mitotic cells) and BT549 
(31 ± 1.6%) breast cancer cells (Supplementary Fig. S2A). In contrast, non-tumorigenic MCF-
10A breast cells were predominantly bipolar and 6 ± 2% of the cell population displayed CA 
(Supplementary Fig. S2A). Each cell model was also immunostained for phosphorylated and 
catalytically active TAOK-pS181 (12, 29), which was detected in the cytoplasm and at the 
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centrosomes of mitotic cells but absent in interphase cells (Supplementary Fig. S2B). Noticeably, 
TAOK-pS181 associated with additional vesicular structures in MCF-10A cells, which are cell 
type specific but remain to be identified (Supplementary Fig. S2B). TAOK1 and TAOK2 
localization in mitotic SKBR3 cells was investigated further by inducing the expression of 
exogenous GFP-tagged TAOK proteins. TAOK1 and TAOK-pS181 colocalize in the cytoplasm 
(Fig. 3A) whereas TAOK2 and TAOK-pS181 colocalize with pericentrin at centrosomes (Fig. 
3B). TAOK1 and TAOK2 are therefore both catalytically active during mitosis but localize to 
different cellular sites. 
The TAOK inhibitor increases the mitotic population and enhances centrosome and 
spindle abnormalities in CA cells 
The requirement for TAOK activity during mitosis was investigated by treating centrosome 
amplified (CA) or bipolar cell models with compound 43 and determining changes in cell cycle 
distribution using flow cytometry. The percentages of total CA SKBR3 cells in mitosis increased 
from 1.28 ± 0.22% to 13.54 ± 0.27% after 24 hours of incubation with the TAOK inhibitor and 
declined thereafter (Fig. 4A, bar chart). The percentages of CA BT549 cells in mitosis also 
increased from 3.01 ± 0.67% to 9.42 ± 1.0% following treatment with compound 43 for 24 hours 
(Fig. 4A). In contrast, the percentages of bipolar and non-tumorigenic MCF-10A cells in mitosis 
were 3.82 ± 0.43% when cultures were incubated for 24 hours with compound 43 (Fig. 4A). 
Analysis of immunostained mitotic cells by confocal microscopy showed that the percentages of 
mitotic SKBR3 and BT549 cells displaying abnormal centrosomes (> 2) or multipolar spindles 
also increased following treatment with compound 43, whereas no significant change in either 
phenotype were observed when the TAOK inhibitor was added to MCF-10A cells (Fig. 4B-C). 
Furthermore, siRNA depletion of TAOK1 and TAOK2 expression together but not separately, 
increased the percentages of mitotic SKBR3 or BT549 cells exhibiting abnormal centrosomes (> 
2), whereas knockdown of either TAOK1 or TAOK2 was sufficient to enhance the occurrence of 
multipolar spindles (Fig. 4D-E). None of these changes were apparent in mitotic MCF-10A cells 
with depleted expression of TAOK1 and/or TAOK2 (Fig. 4D-E). Knockdown of TAOK 
expression was confirmed in all experiments by immunoblotting cell lysates (Supplementary Fig. 
S3). CA SKBR3 and BT549 breast cancer cells therefore appear more dependent on TAOK 
activity during mitosis than non-tumorigenic and bipolar MCF-10A cells.  
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The TAOK inhibitor prolongs mitosis and promotes cell death in dividing SKBR3 cells 
To investigate the effects of the TAOK inhibitor during mitosis, we prepared MCF-10A and 
SKBR3 cell lines expressing GFP-α-tubulin constitutively and used time-lapse video 
microscopy. Detailed image analysis showed that SKBR3 cells displayed a mixed mitotic 
phenotype where 38 ± 1.2% of dividing cells exhibited supernumerary centrosomes and the 
remaining 62 ± 2% of cells contained two centrosomes and were bipolar. Consequently, bipolar 
or multipolar SKBR3 cells were scored separately. Each cell culture well was imaged for 48 
hours, and the length of time taken between nuclear envelope breakdown and cytokinesis 
measured for individual cells. Both cell models divide and proliferate under control conditions, 
although the time taken to complete mitosis was longer in SKBR3 than MCF-10A cells (Fig. 
5A). Live cell imaging also showed that MCF-10A cells divide and progress through mitosis in a 
normal time frame when incubated with or without compound 43 in the culture medium (Fig. 5B 
and Supplementary Movies S1 and S2 showing representative videos). In contrast, addition of 
the TAOK inhibitor to SKBR3 cells caused significant increases in the average duration of 
mitosis in bipolar SKBR3 cells from 89.7 to 465.8 minutes and from 168.3 to 634.3 minutes in 
multipolar SKBR3 cells (Fig. 5B and Supplementary Movies S3 and S4 showing representative 
videos). Further analysis of these videos recording the progression of individual SKBR3 cells 
through mitosis, showed that compound 43 caused 19 ± 12% of bipolar cells or 53 ± 14% of 
multipolar cells to undergo death in mitosis, whilst the remaining cells exited mitosis and some 
of these cells are likely to undergo cell death or senescence in the subsequent G1 phase (Fig. 
5C). Notably, the average length of time that MCF-10A cells spend in mitosis did not change 
significantly in the presence of compound 43 (55 ± 4.4 minutes) and these cells remained viable 
and continued to proliferate (Fig. 5B and Supplementary Movies S1 and S2). 
The TAOK inhibitor induces cell death and inhibits growth of SKBR3 cells 
The live imaging results suggest that CA SKBR3 cells are more dependent on TAOK activity for 
their survival and division than MCF-10A cells. Consequently, the effects of the TAOK inhibitor 
on MCF-10A and SKBR3 cell viability were investigated next using Annexin V staining and 
flow cytometry. Treatment with compound 43 caused a significant increase in the percentages of 
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total SKBR3 cells undergoing cell death from 14.8 ± 1.9% (control) to 30.5 ± 5.4% (24 hours) 
and 42.4 ± 4.9% (48 hours) (Fig. 6A, bar chart). In contrast, the percentages of total MCF-10A 
cells undergoing apoptosis were 13.0 ± 3.4% (control) and increased to 15.1 ± 2.9% (24 hours) 
and 22.6 ± 3.8% (48 hours) after treatment with the TAOK inhibitor (Fig. 6A). The effect of the 
TAOK inhibitor on the growth of MCF-10A, SKBR3 and BT549 cells was also investigated. 
Each cell line was incubated with or without compound 43 and cell numbers determined after 72 
hours. Compound 43 reduced SKBR3 and BT549 cell numbers per dish by 94 ± 3% or 82 ± 
1.9% respectively, when compared to untreated control cultures (Fig. 6B). In comparison, MCF-
10A cell numbers were reduced by 46 ± 10.3%, when compared to untreated cells (Fig. 6B). 
SiRNA depletion of either TAOK1 or TAOK2 expression also caused significant reductions in 
SKBR3 and BT549 cell numbers when compared to control cultures (Fig. 6C) whereas  MCF-
10A cell numbers were not significantly reduced following depletion of TAOK1 and/or TAOK2 
and these cells continued to grow (Fig. 6C and Supplementary Fig. S3). SiRNAs targeting 
TAOK1 and TAOK2 did not completely abolish protein expression and this approach was less 
effective than compound 43 in inhibiting CA cell growth (Supplementary Fig. S3). The effect of 
compound 43 on soft agar growth of MCF-10A and SKBR3 cells was also compared over 21 
days; the TAOK inhibitor decreased colony numbers by 28% or 94% respectively (Fig. 6D). 
Taken together, these results show that CA SKBR3 or BT549 breast cancer cells are more 
dependent on TAOK activity for their viability and growth when compared to non-tumorigenic 
and bipolar MCF-10A breast cells. 
Discussion 
Previous reports describing small molecule inhibitors for TAOKs are limited but have indicated 
that the protein kinase C inhibitor staurosporine inhibits TAOK2 with an IC50 value of 3 µM and 
the mammalian STE20-like kinase 1 inhibitor 9E1 reduces TAOK2 activity with an IC50 value of 
0.3 µM (30, 31). However, staurosporine and 9E1 were shown to inhibit many other kinases 
more potently. A recent high throughput screen has also identified two compounds, SW034538 
and SW083688, that inhibit TAOK2 activity with IC50 values of 300 nM and 1.3 µM respectively 
however, further biological characterization of both small molecules is required (32). In this 
study, we have shown that compounds 43 and 63 act potently to inhibit the activity of TAOK1 
and TAOK2 with IC50 values of 11-15 nM and 19-39 nM respectively, are ATP-competitive and 
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inhibit the catalytic activity of these kinases preferentially in an assay of 70 kinases. Moreover, 
activation of JNK MAPK by exogenous cellular TAOK1 or TAOK2 was inhibited by compound 
43 demonstrating that this small molecule is an effective inhibitor for TAOKs. 
Supernumerary amplified centrosomes typify high grade or invasive breast cancer tissues, and 
appropriate cell models were selected here to represent the aberrant or normal phenotypes (27, 
28, 33, 34). Immunostaining experiments showed that TAOKs are phosphorylated and activated 
specifically during mitosis and that TAOK1 and TAOK2 localized to the cytoplasm or 
centrosomes respectively (12). Inhibition or depletion of TAOKs increased the mitotic 
population and enhanced the occurrence of supernumerary centrosomes and multipolar spindles 
in dividing CA SKBR3 and BT549 cells. In contrast, bipolar and non-tumorigenic MCF-10A 
cells remained bipolar and continued to proliferate. Live cell imaging of SKBR3 cells treated 
with compound 43 showed that the duration of mitosis increased and that these cells either failed 
to exit mitosis and underwent cell death in mitosis or exited mitosis after a significant delay. A 
subpopulation of SKBR3 cells that undergo bipolar mitosis was also susceptible to the TAOK 
inhibitor and a significant proportion of these cells also underwent prolonged mitosis and died. 
In contrast, MCF-10A cells appeared less dependent on TAOK activity and completed mitosis in 
the presence of compound 43 in a normal time frame and a bipolar manner, before dividing.  
A strong correlation exists between CA and genomic instability (CIN) in breast cancer indicating 
that this abnormal phenotype is likely to contribute to chromosome missegregation and 
tumorigenesis (28, 34, 35). Supernumerary centrosomes also cause multipolar mitosis and 
produce nonviable progeny cells owing to lethal gain or loss of chromosomes (17, 36). 
Malignant and CA cells can however enhance their survival by clustering extra centrosomes to 
form a pseudo-bipolar spindle, which reduces multipolarity and associated lethal chromosome 
segregation defects (17, 36, 37). Such cells frequently delay metaphase to allow sufficient MT-
kinetochore capture and/or tensions to occur to satisfy the spindle assembly checkpoint, whilst 
supernumerary centrosomes are also clustered prior to the onset of anaphase (17, 36, 38). In this 
study and consistent with these previous observations, the duration of mitosis is longer in 
SKBR3 cells than MCF-10A cells. The TAOK inhibitor prolonged the length of mitosis in 
SKBR3 cells associated with multipolar mitosis, probably due to centrosome declustering, and 
enhanced cell death in mitosis. In contrast, MCF-10A cells completed mitosis in a normal time 
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frame and a bipolar manner in the presence of compound 43, and these cells continued to divide 
and proliferate. SKBR3 cells required TAOK activity for mitotic progression to avoid enhanced 
multipolarity and associated cell death.  
Centrosome amplification can occur due to endoreduplication, cytokinesis failure, cell-cell 
fusion, PCM fragmentation or dysregulation of the centrosome cycle (28). However, the 
mechanisms involved in clustering supernumerary centrosomes are poorly defined. SiRNA 
screens and live cell imaging studies have implicated functional roles for components of the 
spindle checkpoint (e.g. Mad2, Bub1 and CENP-E), which are likely activated by incorrect 
kinetochore-MT attachments and/or tensions, and subsequently delay metaphase to allow 
centrosome clustering to take place (17, 36, 38). Clustering of centrosomes also requires 
additional proteins involved in regulating the actin-MT cytoskeleton and spindle positioning (e.g. 
Myo10A/Myo15 and CLIP190), as well as MAPs and motor proteins, which bundle MTs at the 
spindle poles (e.g. HSET/KIFC1, Ncd) (38, 39). An additional siRNA screen has identified 
centrosome clustering roles for E3 ubiquitin ligase APC/C subunits and their cofactors Cdh1 and 
Cdc20 and their substrates (e.g. Eg5 motor protein), dynein/dynactin and SKA1-3 complexes 
(40). The screen suggested potential roles for TAOKs, the TAOK binding protein testis-specific 
kinase (TESK) 1 and LIM domain kinase (LIMK) 2 in the regulation of centrosome clustering 
(40, 41). TESKs and the related LIMKs can downregulate activity of the actin-severing protein 
cofilin via phosphorylation, and a mechanism whereby centrosome clustering is inhibited via 
cofilin-mediated destabilization of cortical actin has been reported (42).  
TAOKs can regulate MT dynamics and organization and their activity is required for mitotic cell 
rounding and spindle positioning in HeLa cells (7-9, 12). The evaluation of a first generation 
TAOK inhibitor here has implicated additional roles for these proteins in regulating the 
clustering of supernumerary centrosomes to produce a functional pseudo-bipolar spindle in CA 
breast cancer cells, and a requirement for TAOK activity for such cells to survive and grow. The 
exact role of TAOK inhibition in centrosome declustering requires further mechanistic 
dissection. MT poisons or inhibitors of mitotic kinases such as Aurora and Polo-like kinases or 
motor proteins (e.g. Eg5) can provide effective cancer therapy, however, such inhibitors are also 
associated with extreme toxicity and adverse side effects (14, 15, 23-25, 43). Inhibitors of 
monopolar spindle kinase 1 and the spindle assembly checkpoint have also entered clinical trials 
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although these compounds appear to exhibit only moderate efficacy as single agents and are 
more effective when used in combination with drugs such as paclitaxel (44-46). Additional 
therapeutic strategies are now required to target cancer specific events and drugs that stimulate 
centrosome declustering and multipolarity are likely to kill CA cancer cells selectively, whilst 
sparing normal cells (47). The results reported here provide the first indication that TAOKs may 
provide suitable targets to inhibit and kill CA breast cancer cells selectively. Additional studies 
are now required for further evaluation of TAOKs as potential drug targets for cancer therapy. 
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Figure Legends 
Figure 1.  
Small molecule inhibitors for TAOKs. A, chemical structure of compounds 43 and 63. B, 
calculated IC50 values for compounds 43 and 63 and their inhibition of MBP phosphorylation by 
TAOKs. C, effects of compound 43 or 63 (0.3 µM) on the catalytic activity of different kinases 
and phosphorylation of their substrate relative to control samples (n = 2).  
Figure 2.  
Compound 43 inhibits phosphorylation and activation of JNK by TAOKs in cells. COS1 cells 
were cotransfected with FLAG-JNK and either A, pRK5-MYC (MYC-Empty Vector), pRK5-
MYC-TAOK1 or pRK5-MYC-TAOK1 (K57A) or B, pRK5-MYC, MYC-TAOK2 or MYC-
TAOK2 (K57A), and treated with compound 43 (0-60 µM) as indicated. After 24 hours FLAG-
JNK was immunoprecipitated from cell lysates and bead pellets immunoblotted for FLAG-JNK-
pT183/Y185 or total FLAG-JNK. Cell lysates were also immunoblotted for expression of 
transfected FLAG-JNK, MYC-TAOK1 or MYC-TAOK2. A-B, changes in immunoprecipitated 
FLAG-JNK-pT183/Y185 band intensity relative to total FLAG-JNK (100%) are shown. **, P < 
0.01; n = 3. 
Figure 3.  
TAOK1 and TAOK2 localize to the cytoplasm and centrosomes respectively during mitosis. 
SKBR3 cells expressing A, GFP-TAOK1 or B, GFP-TAOK2 were fixed and costained with 
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antibodies to detect TAOK1, TAOK2, TAOK-pS181, α-tubulin, pericentrin plus DAPI. 
Representative confocal images are shown. Scale bar: 10 µm.  
Figure 4.  
TAOK inhibition increases the mitotic population and the frequency of CA and multipolarity in 
dividing SKBR3 and BT549 cells. MCF-10A, SKBR3 and BT549 cells were treated with or 
without compound 43 (10 µM, 24 or 48 hours, A-C) or transfected with siRNA (48 hours, D-E) 
as indicated. A, cultures were stained with Alexa-Fluor488-histoneH3-pS10 antibody (mitosis) 
and PI (DNA). Flow cytometric profiles of cell cycle distribution are presented in a 
representative Figure and mitotic cells boxed (M). Quantitative analysis of FACS data and 
changes in % of cells in mitosis are shown. B-C, cells were fixed and stained with pericentrin 
and α-tubulin antibodies plus DAPI and % mitotic cells with >2 centrosomes (B) or with 
multipolar spindles (C) determined. D-E, cultures were transfected with nontargeting siRNA 
(siControl) or individual oligonucleotides targeting TAOK1 (siT1-1, siT1-4) or TAOK2 (siT2-1, 
siT2-4). After 48 hours, cultures were fixed and stained with pericentrin and α-tubulin antibodies 
plus DAPI and % mitotic cells with >2 centrosomes (D) or multipolar spindles (E) determined. 
>150 mitotic cells were analyzed in each experiment, *P<0.05, **, P < 0.01  and ***, P < 0.001; 
n = 3.  
 
Figure 5.  
Compound 43 prolongs mitosis and causes death in dividing SKBR3 cells. MCF-10A or SKBR3 
cells expressing fluorescent GFP-α-tubulin were monitored using time-lapse video microscopy 
and individual mitotic cells analyzed. A-B, results showing the time taken for MCF-10A or 
SKBR3 (bipolar or multipolar) cells to complete mitosis in the absence or presence of compound 
43 (5 µM). Scale bar: 10µm. ***, P < 0.001. C, the percentages of dividing SKBR3 cells 
undergoing death in mitosis or exiting mitosis in the presence of compound 43 (48 hours). >120 
mitotic cells were analyzed for each condition and per experiment (n = 3). Representative time-
lapse images are shown in Supplementary Movies S1-S4. 
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Figure 6 
TAOK inhibition reduces SKBR3 cell viability and growth. A, MCF-10A or SKBR3 cells were 
incubated without (control) or with compound 43, fixed and stained with AlexaFluor488-
annexinV (apoptosis) and PI (DNA), and analysed by FACS to identify live cells (V), early (E) 
or late (L) apoptotic cells or necrotic (N) cells. A representative Figure and quantitative analysis 
of FACS data are shown. B, MCF-10A, SKBR3 or BT549 cells were incubated with compound 
43 (10 µM) where indicated and cells detached after 72 hours and counted C, MCF-10A, SKBR3 
or BT549 cells were transfected with nontargeting siRNA (siControl) or individual 
oligonucleotides targeting TAOK1 (siT1-1, siT1-4) or TAOK2 (siT2-1, siT2-4) as indicated and 
cells detached (72 hours) and counted D, MCF-10A or SKBR3 cells were incubated with or 
without compound 43 (10 µM) as indicated. After 21 days, colony numbers per plate were 
determined relative to control cultures (100%). *, P < 0.05, **, P < 0.01 and ***, P < 0.001; n = 
3.  
 
 
